China Healthcare:Further execution in 19provinces

类别:行业研究 机构:国信证券(香港)金融控股有限公司 研究员:Jason Siu 日期:2017-10-12

On 20 Sept 2017, Economics Information Daily (经济参考报) reported that fouradditional provinces, namely Jiangxi, Yunnan, Gansu and Shanxi, had included 36high-priced medicines into their provincial reimbursement drug list (RDL). Thesedrug names are the same as those shortlisted by the national government on 19July. Including these four provinces, it should now have over 19 provinces to addthese 36 drugs into their RDL.

    The article highlighted that, as imported drugs can now be included into RDL at thebigger expense of selling prices, this makes the cheaper local-made medicines tobe less competitive in the market. In addition, the national government will try toimplement this bigger price cut mechanism on high-priced medicines in exchangefor their volume jump in most provinces. Coupled with good surveillance of drugcost spending, Chinese government aims to curb the over-usage of these highpriceddrugs, including monoclonal antibodies.

    The same source also cited that, with the drug cost reimbursement amount fixedby the government post negotiation, it would be unlikely to see bigger selling pricefluctuations to hospitals for these high-priced medicines. Whereby these drugs areusually (1) to treat critical and rare diseases such as cancers; and (2) hard toproduce with good barriers of entry.

    As we flagged in our 12 Sept 2017 note, we see these drugs with clinicalimportance would likely have their sales volume rebound (in particular to foreigndrugs), at the expense of their selling prices, similar to the case with GSK’sTenofovir Disoproxil Fumarate (Viread?). Consistent with national governmentpolicy, it aims to provide Chinese masses accessible to cheaper quality medicinewith good efficacies. We expect this will increase the likelihood for many provincesto introduce further price cut on domestic drugs for critical illness, such as anticancerand stroke medicines.

    Stock impact: This will dampen the sentiment of local drug-maker sector in theshort-term, despite of potential sales volume rebound for these import drugs fromsacrificing their selling prices. Same as we mentioned, we do not surprise to seefurther tough policy (such as price cut) on domestic high-priced drugs such aschemical drugs and monoclonal antibodies for anti-cancer therapy. Aside fromChina Medical System’s (867.HK, NR) XinHuoSu (新活素?; Nesiritide?), we see thismay also affect HK-listed CSPC (1093.HK, NR)’s future pricing on its Bortezomib forinjection (硼替佐米) as a first-to-market generic drug, which is currently on thathigh-priced drug list. Note that, CSPC has applied for production approval fromCFDA, likely to be on sales in the next 12 to 16 months.



九华旅游 买入 -- 研报
天目湖 买入 -- 研报
长白山 买入 -- 研报
黄山旅游 买入 -- 研报
宋城演艺 持有 -- 研报
丽江旅游 买入 -- 研报
桂林旅游 买入 -- 研报
峨眉山A 持有 -- 研报
张家界 买入 -- 研报
广州酒家 买入 -- 研报
中国国旅 买入 -- 研报


全聚德 0.79 1.13 研报
中国国旅 0.76 1.12 研报
众信旅游 0 0 研报
腾邦国际 0.79 0.59 研报
凯撒旅游 0.14 0 研报
西安饮食 0.25 0.18 研报
广州酒家 0 0 研报
云南旅游 0.07 0.07 研报
三湘印象 0 0.51 研报
西安旅游 0.27 0.21 研报
三特索道 0.34 0.44 研报


碧水源 34 持有 持有
中炬高新 33 持有 持有
洋河股份 33 持有 持有
山西汾酒 31 持有 持有
伊利股份 31 持有 持有
烽火通信 30 持有 持有
水井坊 30 持有 持有
先导智能 30 持有 持有
华鲁恒升 29 持有 持有
恒立液压 29 持有 持有
五粮液 29 持有 持有
爱尔眼科 29 持有 持有
三一重工 28 持有 持有
上汽集团 28 持有 持有
泸州老窖 28 持有 持有
分众传媒 28 持有 持有
金风科技 28 持有 持有


电子信息 1178 108 343
汽车制造 774 43 186
机械行业 718 75 189
生物制药 684 72 120
化工行业 642 59 180
农林牧渔 596 32 210
食品行业 581 32 188
酿酒行业 556 17 114
交通运输 508 40 84
金融行业 493 28 209
房地产 431 43 125
建筑建材 424 50 174
电子器件 388 62 125
酒店旅游 325 23 113
钢铁行业 324 23 127
环保行业 317 18 77
商业百货 308 48 84